Christopher Causey Sells 2,240 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 2,240 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

UTHR stock opened at $266.22 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $266.65. The company has a market cap of $11.81 billion, a P/E ratio of 12.59 and a beta of 0.54. The stock’s fifty day moving average price is $238.38 and its 200-day moving average price is $229.88.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. During the same period last year, the firm posted $4.86 earnings per share. The business’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on UTHR shares. SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wells Fargo & Company increased their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Rise Advisors LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics during the fourth quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. increased its position in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. bought a new position in shares of United Therapeutics in the third quarter worth about $91,000. Finally, Janiczek Wealth Management LLC lifted its position in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.